Determining the mechanisms behind goblet cell dysfunction
This project aims to investigate how inflammation, autophagy, and antibiotics affect goblet cell function in IBD using a novel mouse model to enhance understanding and potential therapies.
Projectdetails
Introduction
Goblet cells are specialized epithelial cells that secrete mucus and antimicrobial proteins which together form the gut mucus barrier. The mucus barrier protects the host from bacterial invasion and subsequent activation of an inflammatory response, while also providing food for the microbiome.
Goblet Cell Dysfunction
Dysfunction of goblet cells and high penetrability of the mucus barrier are hallmarks of inflammatory bowel diseases (IBD). While the reasons for goblet cell dysfunction are unclear, it is thought that inflammation, host genetics (specifically mutations in autophagy genes), and environmental factors can affect their function.
Challenges in Understanding Goblet Cells
Yet despite their importance, the basic biology of goblet cells is not understood as they are part of a heterogeneous tissue.
New Mouse Model Development
I developed a new mouse model that allows isolation of ribosomes specifically from goblet cells in vivo, thus revealing the translational response of goblet cells to various conditions.
Preliminary Findings
In preliminary studies, we found that:
- Altering the autophagy process in vivo led to modification of the colonic mucus barrier, alteration of the microbiome, and resistance to colitis.
- Antibiotic treatment, an environmental factor which increases the risk for IBD, altered the mucus barrier and instigated gut inflammation in mice.
Research Goals
Our goal is to mechanistically determine how inflammation, autophagy, and antibiotics affect goblet cell function during health and IBD. We will:
- Define goblet cell function during IBD development in vivo and test if goblet cells fail to regain proper function during remission, leading to relapse.
- Use a novel mouse model of augmented autophagy to determine the role of autophagy in preserving goblet cell function during IBD.
- Use germ-free mice to reveal the microbiome-dependent and -independent effects of antibiotics on goblet cell function and IBD.
Conclusion
Our study will provide new understanding of goblet cell biology and may lead to new therapeutics which target goblet cells.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.361 |
Totale projectbegroting | € 1.499.361 |
Tijdlijn
Startdatum | 1-2-2022 |
Einddatum | 31-1-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- BAR ILAN UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Innovative mucus secretion stimulation for inflammation control in Inflammatory Bowel DiseaseThe project aims to pharmacologically induce intestinal mucus production in preclinical mouse models of IBD to achieve sustained remission, addressing the need for non-immunosuppressive treatments. | ERC Proof of... | € 150.000 | 2024 | Details |
The role of GPCRs and homing molecules in the control and regionalization of mucosal immunity.This project aims to investigate the role of GPCRs, particularly GPR35, in immune regionalization of mucosal tissues to enhance understanding and treatment of gut and airway diseases. | ERC Starting... | € 1.500.000 | 2024 | Details |
Metabolic Gut Inflammation in Crohn's diseaseThis project aims to investigate how dietary polyunsaturated fatty acids trigger gut inflammation in Crohn's disease, establishing a link between diet and disease progression for potential therapeutic strategies. | ERC Starting... | € 1.493.875 | 2022 | Details |
Mucociliary adaptations and gut microbiome establishment in XenopusThe MAGIX project aims to uncover mechanisms controlling cell type compositions in mucociliary epithelia to predict organ functions and address diseases linked to these adaptations. | ERC Consolid... | € 1.995.921 | 2025 | Details |
Deciphering host-gut microbiota spatio-functional plasticity in inflammationThis project aims to investigate the spatiofunctional plasticity of gut bacteria in Crohn's disease, exploring host-microbe interactions and their impact on inflammation using advanced microbiological and immunological methods. | ERC Starting... | € 1.997.500 | 2023 | Details |
Innovative mucus secretion stimulation for inflammation control in Inflammatory Bowel Disease
The project aims to pharmacologically induce intestinal mucus production in preclinical mouse models of IBD to achieve sustained remission, addressing the need for non-immunosuppressive treatments.
The role of GPCRs and homing molecules in the control and regionalization of mucosal immunity.
This project aims to investigate the role of GPCRs, particularly GPR35, in immune regionalization of mucosal tissues to enhance understanding and treatment of gut and airway diseases.
Metabolic Gut Inflammation in Crohn's disease
This project aims to investigate how dietary polyunsaturated fatty acids trigger gut inflammation in Crohn's disease, establishing a link between diet and disease progression for potential therapeutic strategies.
Mucociliary adaptations and gut microbiome establishment in Xenopus
The MAGIX project aims to uncover mechanisms controlling cell type compositions in mucociliary epithelia to predict organ functions and address diseases linked to these adaptations.
Deciphering host-gut microbiota spatio-functional plasticity in inflammation
This project aims to investigate the spatiofunctional plasticity of gut bacteria in Crohn's disease, exploring host-microbe interactions and their impact on inflammation using advanced microbiological and immunological methods.